Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of September 2025 for Nasus Pharma Ltd., a foreign private issuer based in Tel Aviv, Israel. The report details the closing of the partial exercise of the over-allotment option related to the Company's initial public offering (IPO).
Key Financial Metrics
- Net Proceeds from Over-Allotment: Approximately $28,000 (after underwriting discount).
- Total Net IPO Proceeds: Approximately $8.8 million (after underwriting discount and estimated offering expenses).
- Shares Issued in Over-Allotment: 3,824 ordinary shares.
- IPO Price: $8.00 per share.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for operating revenue, net profit, or operating cash flow.
- Debt and Liquidity: The filing text does not provide a clear value for total debt or specific liquidity ratios beyond the cash proceeds noted above.
Material Changes
The primary material change reported is the increase in total capital raised from the IPO following the partial exercise of the underwriters' over-allotment option. This transaction increased the total net proceeds to approximately $8.8 million.
Guidance, Outlook, and Risks
Use of Proceeds: The Company intends to utilize the IPO proceeds for the development of its intranasal Epinephrine program, specifically for manufacturing scale-up and additional Phase 2 studies. Remaining funds will be allocated to general and administrative corporate purposes, including working capital and capital expenditures.
Risks and Forward-Looking Statements: The filing contains forward-looking statements regarding the expected use of proceeds and future development. These statements are subject to substantial risks and uncertainties, including assumptions about future events that may not prove accurate. Detailed risk factors are referenced in the final prospectus filed with the SEC.
Investor Verification Checklist
- Verify the final prospectus (File No. 333-288582) for detailed risk factors and full financial statements.
- Confirm the specific timeline and milestones for the intranasal Epinephrine Phase 2 studies.
- Review the Company's cash burn rate and runway given the $8.8 million in total net proceeds.
- Check for any subsequent filings regarding the full exercise of the over-allotment option or changes in the use of proceeds.